Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 34 of 34 entries
Sorted by: Best Match Show Resources per page
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.

Blood

Caulier A, Roussel M, Morel P, Lombion N, Branco B, Galtier J, Hulin C, Perrot A, Richez V, Michaud AV, Touzeau C, Doyen C, Mariette C, Caillot D, Harel S, Lenain P, Ivanoff S, Fontan J, Stoppa AM, Manier S, Garderet L, Leleu X, Marolleau JP, Arnulf B, Avet-Loiseau H, Royer B.
PMID: 34479366
Blood. 2021 Dec 23;138(25):2686-2695. doi: 10.1182/blood.2021011285.

Multiple myeloma (MM) is rare in young patients, especially before age 40 years at diagnosis, representing

Cite
Caulier A, Roussel M, Morel P, et al. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood. 2021;138(25):2686-2695doi: 10.1182/blood.2021011285.
Caulier, A., Roussel, M., Morel, P., Lombion, N., Branco, B., Galtier, J., Hulin, C., Perrot, A., Richez, V., Michaud, A. V., Touzeau, C., Doyen, C., Mariette, C., Caillot, D., Harel, S., Lenain, P., Ivanoff, S., Fontan, J., Stoppa, A. M., Manier, S., Garderet, L., Leleu, X., Marolleau, J. P., Arnulf, B., Avet-Loiseau, H., & Royer, B. (2021). Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood, 138(25), 2686-2695. https://doi.org/10.1182/blood.2021011285
Caulier, Alexis, et al. "Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience." Blood vol. 138,25 (2021): 2686-2695. doi: https://doi.org/10.1182/blood.2021011285
Caulier A, Roussel M, Morel P, Lombion N, Branco B, Galtier J, Hulin C, Perrot A, Richez V, Michaud AV, Touzeau C, Doyen C, Mariette C, Caillot D, Harel S, Lenain P, Ivanoff S, Fontan J, Stoppa AM, Manier S, Garderet L, Leleu X, Marolleau JP, Arnulf B, Avet-Loiseau H, Royer B. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood. 2021 Dec 23;138(25):2686-2695. doi: 10.1182/blood.2021011285. PMID: 34479366.
Copy Download .nbib Format: NLM
Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype.

Cancers

Fenwarth L, Duployez N, Thomas X, Boissel N, Geffroy S, Marceau-Renaut A, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Cheok MH, Peyrouze P, Pigneux A, Vey N, Celli-Lebras K, Terré C, Preudhomme C, Dombret H.
PMID: 31905904
Cancers (Basel). 2019 Dec 30;12(1). doi: 10.3390/cancers12010088.

Acute myeloid leukemia (AML) encompasses heterogeneous entities with dismal outcomes. Intermediate and unfavorable-risk AML represent the most difficult-to-treat entities. We recently reported the benefit of the clofarabine-based consolidation (CLARA) regimen compared to the standard high-dose cytarabine (HDAC) regimen in...

Cite
Fenwarth L, Duployez N, Thomas X, et al. Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype. Cancers (Basel). 2019;12(1)doi: 10.3390/cancers12010088.
Fenwarth, L., Duployez, N., Thomas, X., Boissel, N., Geffroy, S., Marceau-Renaut, A., Caillot, D., Raffoux, E., Lemasle, E., Marolleau, J. P., Berthon, C., Cheok, M. H., Peyrouze, P., Pigneux, A., Vey, N., Celli-Lebras, K., Terré, C., Preudhomme, C., & Dombret, H. (2019). Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype. Cancers, 12(1), . https://doi.org/10.3390/cancers12010088
Fenwarth, Laurène, et al. "Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype." Cancers vol. 12,1 (2019). doi: https://doi.org/10.3390/cancers12010088
Fenwarth L, Duployez N, Thomas X, Boissel N, Geffroy S, Marceau-Renaut A, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Cheok MH, Peyrouze P, Pigneux A, Vey N, Celli-Lebras K, Terré C, Preudhomme C, Dombret H. Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype. Cancers (Basel). 2019 Dec 30;12(1). doi: 10.3390/cancers12010088. PMID: 31905904; PMCID: PMC7017244.
Copy Download .nbib Format: NLM
Beneficial outcomes and epidemiologics of atypical electrophoretic profiles arising after allogeneic hematopoietic stem cell transplantation for myeloid malignancies.

Current research in translational medicine

Hedhli K, Clichet V, Charbonnier A, Castelain S, Galmiche A, Marolleau JP, Boyer T, Caulier A, Sauzay C.
PMID: 34801813
Curr Res Transl Med. 2021 Nov 18;70(1):103322. doi: 10.1016/j.retram.2021.103322. Epub 2021 Nov 18.

PURPOSE OF THE STUDY: Atypical serum protein electrophoresis (SPE) profiles may arise in patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT), but little is known about their clinical significance. Atypical SPE combine either monoclonal and oligoclonal components, suspected...

Cite
Hedhli K, Clichet V, Charbonnier A, et al. Beneficial outcomes and epidemiologics of atypical electrophoretic profiles arising after allogeneic hematopoietic stem cell transplantation for myeloid malignancies. Curr Res Transl Med. 2021;70(1):103322doi: 10.1016/j.retram.2021.103322.
Hedhli, K., Clichet, V., Charbonnier, A., Castelain, S., Galmiche, A., Marolleau, J. P., Boyer, T., Caulier, A., & Sauzay, C. (2021). Beneficial outcomes and epidemiologics of atypical electrophoretic profiles arising after allogeneic hematopoietic stem cell transplantation for myeloid malignancies. Current research in translational medicine, 70(1), 103322. https://doi.org/10.1016/j.retram.2021.103322
Hedhli, Kaies, et al. "Beneficial outcomes and epidemiologics of atypical electrophoretic profiles arising after allogeneic hematopoietic stem cell transplantation for myeloid malignancies." Current research in translational medicine vol. 70,1 (2021): 103322. doi: https://doi.org/10.1016/j.retram.2021.103322
Hedhli K, Clichet V, Charbonnier A, Castelain S, Galmiche A, Marolleau JP, Boyer T, Caulier A, Sauzay C. Beneficial outcomes and epidemiologics of atypical electrophoretic profiles arising after allogeneic hematopoietic stem cell transplantation for myeloid malignancies. Curr Res Transl Med. 2021 Nov 18;70(1):103322. doi: 10.1016/j.retram.2021.103322. Epub 2021 Nov 18. PMID: 34801813.
Copy Download .nbib Format: NLM
Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma.

Advances in hematology

Schmidt-Tanguy A, Houot R, Lissandre S, Abgrall JF, Casassus P, Rodon P, Desablens B, Marolleau JP, Garidi R, Lamy T, Moles-Moreau MP, Damaj G.
PMID: 24723955
Adv Hematol. 2014;2014:512508. doi: 10.1155/2014/512508. Epub 2014 Mar 02.

Background. Primary bone lymphoma (PBL) is a rare entity that has only been reviewed in one prospective and small retrospective studies, from which it is difficult to establish treatment guidelines. We prospectively evaluated high-dose or conventional anthracycline-cyclophosphamide dose and...

Cite
Schmidt-Tanguy A, Houot R, Lissandre S, et al. Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma. Adv Hematol. 2014;2014:512508doi: 10.1155/2014/512508.
Schmidt-Tanguy, A., Houot, R., Lissandre, S., Abgrall, J. F., Casassus, P., Rodon, P., Desablens, B., Marolleau, J. P., Garidi, R., Lamy, T., Moles-Moreau, M. P., & Damaj, G. (2014). Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma. Advances in hematology, 2014512508. https://doi.org/10.1155/2014/512508
Schmidt-Tanguy, A, et al. "Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma." Advances in hematology vol. 2014 (2014): 512508. doi: https://doi.org/10.1155/2014/512508
Schmidt-Tanguy A, Houot R, Lissandre S, Abgrall JF, Casassus P, Rodon P, Desablens B, Marolleau JP, Garidi R, Lamy T, Moles-Moreau MP, Damaj G. Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma. Adv Hematol. 2014;2014:512508. doi: 10.1155/2014/512508. Epub 2014 Mar 02. PMID: 24723955; PMCID: PMC3958647.
Copy Download .nbib Format: NLM
An Alginate-Based Hydrogel with a High Angiogenic Capacity and a High Osteogenic Potential.

BioResearch open access

Barre A, Naudot M, Colin F, Sevestre H, Collet L, Devauchelle B, Lack S, Marolleau JP, Le Ricousse S.
PMID: 32642332
Biores Open Access. 2020 Jun 05;9(1):174-182. doi: 10.1089/biores.2020.0010. eCollection 2020.

In bone tissue engineering, autologous cells are combined with osteoconductive scaffolds and implanted into bone defects. The major challenge is the lack of post-implantation vascular growth into biomaterial. The objective of the present study was to develop a new...

Cite
Barre A, Naudot M, Colin F, et al. An Alginate-Based Hydrogel with a High Angiogenic Capacity and a High Osteogenic Potential. Biores Open Access. 2020;9(1):174-182doi: 10.1089/biores.2020.0010.
Barre, A., Naudot, M., Colin, F., Sevestre, H., Collet, L., Devauchelle, B., Lack, S., Marolleau, J. P., & Le Ricousse, S. (2020). An Alginate-Based Hydrogel with a High Angiogenic Capacity and a High Osteogenic Potential. BioResearch open access, 9(1), 174-182. https://doi.org/10.1089/biores.2020.0010
Barre, Anaïs, et al. "An Alginate-Based Hydrogel with a High Angiogenic Capacity and a High Osteogenic Potential." BioResearch open access vol. 9,1 (2020): 174-182. doi: https://doi.org/10.1089/biores.2020.0010
Barre A, Naudot M, Colin F, Sevestre H, Collet L, Devauchelle B, Lack S, Marolleau JP, Le Ricousse S. An Alginate-Based Hydrogel with a High Angiogenic Capacity and a High Osteogenic Potential. Biores Open Access. 2020 Jun 05;9(1):174-182. doi: 10.1089/biores.2020.0010. eCollection 2020. PMID: 32642332; PMCID: PMC7337169.
Copy Download .nbib Format: NLM
Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometry.

British journal of haematology

Clichet V, Harrivel V, Delette C, Guiheneuf E, Gautier M, Morel P, Assouan D, Merlusca L, Beaumont M, Lebon D, Caulier A, Marolleau JP, Matthes T, Vergez F, Garçon L, Boyer T.
PMID: 34730236
Br J Haematol. 2021 Nov 03; doi: 10.1111/bjh.17933. Epub 2021 Nov 03.

Monoclonal gammopathy of unknown significance (MGUS), smouldering multiple myeloma (SMM), and multiple myeloma (MM) are very common neoplasms. However, it is often difficult to distinguish between these entities. In the present study, we aimed to classify the most powerful...

Cite
Clichet V, Harrivel V, Delette C, et al. Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometry. Br J Haematol. 2021;doi: 10.1111/bjh.17933.
Clichet, V., Harrivel, V., Delette, C., Guiheneuf, E., Gautier, M., Morel, P., Assouan, D., Merlusca, L., Beaumont, M., Lebon, D., Caulier, A., Marolleau, J. P., Matthes, T., Vergez, F., Garçon, L., & Boyer, T. (2021). Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometry. British journal of haematology, . https://doi.org/10.1111/bjh.17933
Clichet, Valentin, et al. "Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometry." British journal of haematology vol. (2021). doi: https://doi.org/10.1111/bjh.17933
Clichet V, Harrivel V, Delette C, Guiheneuf E, Gautier M, Morel P, Assouan D, Merlusca L, Beaumont M, Lebon D, Caulier A, Marolleau JP, Matthes T, Vergez F, Garçon L, Boyer T. Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometry. Br J Haematol. 2021 Nov 03; doi: 10.1111/bjh.17933. Epub 2021 Nov 03. PMID: 34730236.
Copy Download .nbib Format: NLM
Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias.

Genes, chromosomes & cancer

Lestringant V, Duployez N, Penther D, Luquet I, Derrieux C, Lutun A, Preudhomme C, West M, Ouled-Haddou H, Devoldere C, Marolleau JP, Garçon L, Jedraszak G, Ferret Y.
PMID: 33982372
Genes Chromosomes Cancer. 2021 Oct;60(10):657-667. doi: 10.1002/gcc.22971. Epub 2021 May 26.

Acute lymphoblastic leukemias (ALL) are characterized by a large number of cytogenetic abnormalities of clinical interest that require the use of several complementary techniques. Optical genome mapping (OGM) is based on analysis of ultra-high molecular weight DNA molecules that...

Cite
Lestringant V, Duployez N, Penther D, et al. Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias. Genes Chromosomes Cancer. 2021;60(10):657-667doi: 10.1002/gcc.22971.
Lestringant, V., Duployez, N., Penther, D., Luquet, I., Derrieux, C., Lutun, A., Preudhomme, C., West, M., Ouled-Haddou, H., Devoldere, C., Marolleau, J. P., Garçon, L., Jedraszak, G., & Ferret, Y. (2021). Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias. Genes, chromosomes & cancer, 60(10), 657-667. https://doi.org/10.1002/gcc.22971
Lestringant, Valentin, et al. "Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias." Genes, chromosomes & cancer vol. 60,10 (2021): 657-667. doi: https://doi.org/10.1002/gcc.22971
Lestringant V, Duployez N, Penther D, Luquet I, Derrieux C, Lutun A, Preudhomme C, West M, Ouled-Haddou H, Devoldere C, Marolleau JP, Garçon L, Jedraszak G, Ferret Y. Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias. Genes Chromosomes Cancer. 2021 Oct;60(10):657-667. doi: 10.1002/gcc.22971. Epub 2021 May 26. PMID: 33982372.
Copy Download .nbib Format: NLM
Beneficial outcomes and epidemiologics of atypical electrophoretic profiles arising after allogeneic hematopoietic stem cell transplantation for myeloid malignancies.

Current research in translational medicine

Hedhli K, Clichet V, Charbonnier A, Castelain S, Galmiche A, Marolleau JP, Boyer T, Caulier A, Sauzay C.
PMID: 34801813
Curr Res Transl Med. 2022 Jan;70(1):103322. doi: 10.1016/j.retram.2021.103322. Epub 2021 Nov 19.

PURPOSE OF THE STUDY: Atypical serum protein electrophoresis (SPE) profiles may arise in patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT), but little is known about their clinical significance. Atypical SPE combine either monoclonal and oligoclonal components, suspected...

Cite
Hedhli K, Clichet V, Charbonnier A, et al. Beneficial outcomes and epidemiologics of atypical electrophoretic profiles arising after allogeneic hematopoietic stem cell transplantation for myeloid malignancies. Curr Res Transl Med. 2021;70(1):103322doi: 10.1016/j.retram.2021.103322.
Hedhli, K., Clichet, V., Charbonnier, A., Castelain, S., Galmiche, A., Marolleau, J. P., Boyer, T., Caulier, A., & Sauzay, C. (2022). Beneficial outcomes and epidemiologics of atypical electrophoretic profiles arising after allogeneic hematopoietic stem cell transplantation for myeloid malignancies. Current research in translational medicine, 70(1), 103322. https://doi.org/10.1016/j.retram.2021.103322
Hedhli, Kaies, et al. "Beneficial outcomes and epidemiologics of atypical electrophoretic profiles arising after allogeneic hematopoietic stem cell transplantation for myeloid malignancies." Current research in translational medicine vol. 70,1 (2022): 103322. doi: https://doi.org/10.1016/j.retram.2021.103322
Hedhli K, Clichet V, Charbonnier A, Castelain S, Galmiche A, Marolleau JP, Boyer T, Caulier A, Sauzay C. Beneficial outcomes and epidemiologics of atypical electrophoretic profiles arising after allogeneic hematopoietic stem cell transplantation for myeloid malignancies. Curr Res Transl Med. 2022 Jan;70(1):103322. doi: 10.1016/j.retram.2021.103322. Epub 2021 Nov 19. PMID: 34801813.
Copy Download .nbib Format: NLM
Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.

Clinical lymphoma, myeloma & leukemia

Michallet M, Sobh M, Morisset S, Deloire A, Raffoux E, de Botton S, Caillot D, Chantepie S, Girault S, Berthon C, Bertoli S, Lepretre S, Leguay T, Castaigne S, Marolleau JP, Pautas C, Malfuson JV, Veyn N, Braun T, Gastaud L, Suarez F, Schmidt A, Gressin R, Bonmati C, Celli-Lebras K, El-Hamri M, Ribaud P, Dombret H, Thomas X, Bergeron A.
PMID: 34895843
Clin Lymphoma Myeloma Leuk. 2021 Oct 25; doi: 10.1016/j.clml.2021.10.011. Epub 2021 Oct 25.

BACKGROUND: Although recommended in patients with acute myeloblastic leukaemia (AML) after induction chemotherapy, real-life use of antifungal prophylaxis (AFP) is different among centres.MATERIALS AND METHODS: This is an ancillary study to a randomized trial on intensive induction chemotherapy in...

Cite
Michallet M, Sobh M, Morisset S, et al. Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group. Clin Lymphoma Myeloma Leuk. 2021;doi: 10.1016/j.clml.2021.10.011.
Michallet, M., Sobh, M., Morisset, S., Deloire, A., Raffoux, E., de Botton, S., Caillot, D., Chantepie, S., Girault, S., Berthon, C., Bertoli, S., Lepretre, S., Leguay, T., Castaigne, S., Marolleau, J. P., Pautas, C., Malfuson, J. V., Veyn, N., Braun, T., Gastaud, L., Suarez, F., Schmidt, A., Gressin, R., Bonmati, C., Celli-Lebras, K., El-Hamri, M., Ribaud, P., Dombret, H., Thomas, X., & Bergeron, A. (2021). Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group. Clinical lymphoma, myeloma & leukemia, . https://doi.org/10.1016/j.clml.2021.10.011
Michallet, Mauricette, et al. "Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group." Clinical lymphoma, myeloma & leukemia vol. (2021). doi: https://doi.org/10.1016/j.clml.2021.10.011
Michallet M, Sobh M, Morisset S, Deloire A, Raffoux E, de Botton S, Caillot D, Chantepie S, Girault S, Berthon C, Bertoli S, Lepretre S, Leguay T, Castaigne S, Marolleau JP, Pautas C, Malfuson JV, Veyn N, Braun T, Gastaud L, Suarez F, Schmidt A, Gressin R, Bonmati C, Celli-Lebras K, El-Hamri M, Ribaud P, Dombret H, Thomas X, Bergeron A. Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group. Clin Lymphoma Myeloma Leuk. 2021 Oct 25; doi: 10.1016/j.clml.2021.10.011. Epub 2021 Oct 25. PMID: 34895843.
Copy Download .nbib Format: NLM
EPIDEMIOLOGICAL LANDSCAPE OF YOUNG MULTIPLE MYELOMA PATIENTS DIAGNOSED EARLIER THAN 40 YEARS: THE FRENCH EXPERIENCE.

Blood

Caulier A, Roussel M, Morel P, Lombion N, Branco B, Galtier J, Hulin C, Perrot A, Richez V, Michaud-Robert AV, Touzeau C, Doyen C, Mariette C, Caillot D, Harel S, Lenain P, Ivanoff S, Fontan J, Stoppa AM, Manier S, Garderet L, Leleu X, Marolleau JP, Arnulf B, Avet-Loiseau H, Royer B.
PMID: 34479366
Blood. 2021 Sep 03; doi: 10.1182/blood.2021011285. Epub 2021 Sep 03.

Multiple Myeloma (MM) is rare in young patients - especially before 40 years at diagnosis, representing less than 2% of all patients with MM. Little is known about the disease characteristics and prognosis of these patients. In this study...

Cite
Caulier A, Roussel M, Morel P, et al. EPIDEMIOLOGICAL LANDSCAPE OF YOUNG MULTIPLE MYELOMA PATIENTS DIAGNOSED EARLIER THAN 40 YEARS: THE FRENCH EXPERIENCE. Blood. 2021;doi: 10.1182/blood.2021011285.
Caulier, A., Roussel, M., Morel, P., Lombion, N., Branco, B., Galtier, J., Hulin, C., Perrot, A., Richez, V., Michaud-Robert, A. V., Touzeau, C., Doyen, C., Mariette, C., Caillot, D., Harel, S., Lenain, P., Ivanoff, S., Fontan, J., Stoppa, A. M., Manier, S., Garderet, L., Leleu, X., Marolleau, J. P., Arnulf, B., Avet-Loiseau, H., & Royer, B. (2021). EPIDEMIOLOGICAL LANDSCAPE OF YOUNG MULTIPLE MYELOMA PATIENTS DIAGNOSED EARLIER THAN 40 YEARS: THE FRENCH EXPERIENCE. Blood, . https://doi.org/10.1182/blood.2021011285
Caulier, Alexis, et al. "EPIDEMIOLOGICAL LANDSCAPE OF YOUNG MULTIPLE MYELOMA PATIENTS DIAGNOSED EARLIER THAN 40 YEARS: THE FRENCH EXPERIENCE." Blood vol. (2021). doi: https://doi.org/10.1182/blood.2021011285
Caulier A, Roussel M, Morel P, Lombion N, Branco B, Galtier J, Hulin C, Perrot A, Richez V, Michaud-Robert AV, Touzeau C, Doyen C, Mariette C, Caillot D, Harel S, Lenain P, Ivanoff S, Fontan J, Stoppa AM, Manier S, Garderet L, Leleu X, Marolleau JP, Arnulf B, Avet-Loiseau H, Royer B. EPIDEMIOLOGICAL LANDSCAPE OF YOUNG MULTIPLE MYELOMA PATIENTS DIAGNOSED EARLIER THAN 40 YEARS: THE FRENCH EXPERIENCE. Blood. 2021 Sep 03; doi: 10.1182/blood.2021011285. Epub 2021 Sep 03. PMID: 34479366.
Copy Download .nbib Format: NLM
Showing 25 to 34 of 34 entries